Erroneous exchange of asparaginase forms in the treatment of acute lymphoblastic leukemia

There is no fulltext present in this item.

Title:	Erroneous exchange of asparaginase forms in the treatment of acute lymphoblastic leukemia
Author(s):	Cheung, K.C. ; Bemt, P.M. van den; Torringa, M.L.; Tamminga, R.Y.; Pieters, R.; Smet, P.A. de
Publication year:	2011
Source:	Journal of Pediatric Hematology/Oncology, vol. 33, iss. 3, (2011), pp. e109-13
ISSN:	1077-4114
DOI:	https://doi.org/10.1097/MPH.0b013e3182099a6a
Publication type:	Article / Letter to editor
Please use this identifier to cite or link to this item : https://hdl.handle.net/2066/96881
Display more details
Subject:	N4i 2: Invasive mycoses and compromised host N4i 3: Poverty-related infectious diseases NCEBP 13: Infectious diseases and international health NCEBP 3: Implementation Science NCEBP 3: Implementation Science
Organization:	IQ Healthcare Clinical Pharmacy
Journal title:	Journal of Pediatric Hematology/Oncology
Volume:	vol. 33
Issue:	iss. 3
Page start:	p. e109
Page end:	p. 13
Abstract:	For the treatment of children with acute lymphoblastic leukemia (ALL), Dutch pediatric oncologists use the Dutch Childhood Oncology Group ALL 10 protocol. This protocol is complex, as it comprises many different drug regimens. One of the drugs is asparaginase which is available in different forms with different pharmacokinetics: Escherichia coli asparaginase, Erwinia asparaginase, and pegylated E. coli asparaginase [polyethylene glycol (PEG) asparaginase]. Here, we report the case of a 3-year-old patient treated with ALL who was 8 times erroneously treated with E. coli asparaginase instead of PEG asparaginase. As E. coli asparaginase was administered to the patient in the lower dosage regimen of PEG asparaginase, she was undertreated, but at the end of the treatment the patient was in complete remission. This case report describes the actual course of treatment, the reasons why it went wrong, and possible preventive measures.